-+ 0.00%
-+ 0.00%
-+ 0.00%
Hisco announced that the company's two new Class 1 drugs, cligabarin benzenesulfonate capsules and coglitin tablets, were included in the “National Medical Insurance Catalogue” and are all Class B drugs. Among them, cligabarin benzenesulfonate capsules are used to treat adult diabetic peripheral neuropathic pain and post-herpes zoster neuralgia. The agreement is valid from January 1, 2027 to December 31, 2028; coglitin tablets are used to improve blood sugar control in adult type 2 diabetics. This inclusion in medical insurance is conducive to the marketing of innovative pharmaceutical products and plays a positive role in product sales. The new medical insurance catalogue will be officially implemented on January 1, 2027.
Share
Listen to the news
Hisco announced that the company's two new Class 1 drugs, cligabarin benzenesulfonate capsules and coglitin tablets, were included in the “National Medical Insurance Catalogue” and are all Class B drugs. Among them, cligabarin benzenesulfonate capsules are used to treat adult diabetic peripheral neuropathic pain and post-herpes zoster neuralgia. The agreement is valid from January 1, 2027 to December 31, 2028; coglitin tablets are used to improve blood sugar control in adult type 2 diabetics. This inclusion in medical insurance is conducive to the marketing of innovative pharmaceutical products and plays a positive role in product sales. The new medical insurance catalogue will be officially implemented on January 1, 2027.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending